162 related articles for article (PubMed ID: 38216161)
1. Management of hepatic hydropericardium with open drainage, maximal medical therapy and terlipressin.
Ermongkonchai T; Ha P; French J
BMJ Case Rep; 2024 Jan; 17(1):. PubMed ID: 38216161
[TBL] [Abstract][Full Text] [Related]
2. The use of terlipressin in cirrhotic patients with refractory ascites and normal renal function: a multicentric study.
Fimiani B; Guardia DD; Puoti C; D'Adamo G; Cioffi O; Pagano A; Tagliamonte MR; Izzi A
Eur J Intern Med; 2011 Dec; 22(6):587-90. PubMed ID: 22075285
[TBL] [Abstract][Full Text] [Related]
3. Systemic, portal and renal effects of terlipressin in patients with cirrhotic ascites: pilot study.
Therapondos G; Stanley AJ; Hayes PC
J Gastroenterol Hepatol; 2004 Jan; 19(1):73-7. PubMed ID: 14675246
[TBL] [Abstract][Full Text] [Related]
4. [Observation of the therapeutic and characteristic effects of terlipressin on refractory cirrhotic ascites].
Xing F; Li S; Zhang JJ; Sun CY; Huang JR; Gao ZL; Zhu TT; Zhao Q; Zhang H; Liu CH
Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):982-988. PubMed ID: 31941260
[No Abstract] [Full Text] [Related]
5. Terlipressin versus albumin in paracentesis-induced circulatory dysfunction in cirrhosis: a randomized study.
Singh V; Kumar R; Nain CK; Singh B; Sharma AK
J Gastroenterol Hepatol; 2006 Jan; 21(1 Pt 2):303-7. PubMed ID: 16460491
[TBL] [Abstract][Full Text] [Related]
6. Terlipressin Plus Albumin Is More Effective Than Albumin Alone in Improving Renal Function in Patients With Cirrhosis and Hepatorenal Syndrome Type 1.
Boyer TD; Sanyal AJ; Wong F; Frederick RT; Lake JR; O'Leary JG; Ganger D; Jamil K; Pappas SC;
Gastroenterology; 2016 Jun; 150(7):1579-1589.e2. PubMed ID: 26896734
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the effect of terlipressin and albumin on arterial blood volume in patients with cirrhosis and tense ascites treated by paracentesis: a randomised pilot study.
Moreau R; Asselah T; Condat B; de Kerguenec C; Pessione F; Bernard B; Poynard T; Binn M; Grangé JD; Valla D; Lebrec D
Gut; 2002 Jan; 50(1):90-4. PubMed ID: 11772973
[TBL] [Abstract][Full Text] [Related]
8. Effects of terlipressin on water excretion after oral water load test in nonazotemic cirrhotic patients with ascites without hyponatremia.
Kalambokis GN; Pappas K; Baltayiannis G; Katsanou A; Tsianos EV
Scand J Gastroenterol; 2010 Dec; 45(12):1509-15. PubMed ID: 20695722
[TBL] [Abstract][Full Text] [Related]
9. Hepatic hydropericardium.
Cheung TK; Tam W; Bartholomeusz D; Harley H; Johnson R
J Gastroenterol Hepatol; 2004 Jan; 19(1):109-12. PubMed ID: 14675253
[TBL] [Abstract][Full Text] [Related]
10. Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome.
Neri S; Pulvirenti D; Malaguarnera M; Cosimo BM; Bertino G; Ignaccolo L; Siringo S; Castellino P
Dig Dis Sci; 2008 Mar; 53(3):830-5. PubMed ID: 17939047
[TBL] [Abstract][Full Text] [Related]
11. Hepatorenal syndrome: Current concepts related to diagnosis and management.
de Mattos ÁZ; de Mattos AA; Méndez-Sánchez N
Ann Hepatol; 2016; 15(4):474-81. PubMed ID: 27236146
[TBL] [Abstract][Full Text] [Related]
12. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
[TBL] [Abstract][Full Text] [Related]
13. Treatment of hepatic hydrothorax with terlipressin in a cirrhotic patient.
Ibrisim D; Cakaloglu Y; Akyuz F; Karadag A; Ozdil S; Besisik F; Mungan Z; Okten A
Scand J Gastroenterol; 2006 Jul; 41(7):862-5. PubMed ID: 16785202
[TBL] [Abstract][Full Text] [Related]
14. Dobutamine reverses the cardio-suppressive effects of terlipressin without improving renal function in cirrhosis and ascites: a randomized controlled trial.
Israelsen M; Dahl EK; Madsen BS; Wiese S; Bendtsen F; Møller S; Fialla AD; Jensen BL; Krag A
Am J Physiol Gastrointest Liver Physiol; 2020 Feb; 318(2):G313-G321. PubMed ID: 31841026
[TBL] [Abstract][Full Text] [Related]
15. COST EFFECTIVENESS OF USING TERLIPRESSIN TO TREAT HEPATORENAL SYNDROME.
Ferreira LM; Terrabuio DR; Ferreira CM; Mazo DFC; Haddad LBP
Arq Gastroenterol; 2022; 59(2):268-274. PubMed ID: 35830040
[TBL] [Abstract][Full Text] [Related]
16. AGA Clinical Practice Update on the Evaluation and Management of Acute Kidney Injury in Patients With Cirrhosis: Expert Review.
Flamm SL; Wong F; Ahn J; Kamath PS
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2707-2716. PubMed ID: 36075500
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of terlipressin-related patient outcomes in hepatorenal syndrome-acute kidney injury using point-of-care echocardiography.
Premkumar M; Kajal K; Reddy KR; Izzy M; Kulkarni AV; Duseja AK; Sihag KB; Divyaveer S; Gupta A; Taneja S; De A; Verma N; Rathi S; Bhujade H; Chaluvashetty SB; Roy A; Kumar V; Siddhartha V; Singh V; Bahl A
Hepatology; 2024 May; 79(5):1048-1064. PubMed ID: 37976391
[TBL] [Abstract][Full Text] [Related]
18. Terlipressin and albumin vs albumin in patients with cirrhosis and hepatorenal syndrome: a randomized study.
Martín-Llahí M; Pépin MN; Guevara M; Díaz F; Torre A; Monescillo A; Soriano G; Terra C; Fábrega E; Arroyo V; Rodés J; Ginès P;
Gastroenterology; 2008 May; 134(5):1352-9. PubMed ID: 18471512
[TBL] [Abstract][Full Text] [Related]
19. [Research progress of terlipressin in the treatment of cirrhotic ascites-related complications].
Liu CH; Xing F; Wang J
Zhonghua Gan Zang Bing Za Zhi; 2019 Dec; 27(12):929-932. PubMed ID: 31941255
[TBL] [Abstract][Full Text] [Related]
20. Terlipressin resolves ascites of cirrhotic rats through downregulation of aquaporin 2.
Huang YY; Sun JY; Wang JY; Bai CX; He BM
J Int Med Res; 2012; 40(5):1735-44. PubMed ID: 23206455
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
